Background: Meningococcal disease (MD) is a major cause of meningitis and sepsis worldwide, with a high case fatality rate and frequent sequelae. Neisseria meningitidis serogroups A, B, C, W, X and Y are responsible for most of these life-threatening infections, and its unpredictable epidemiology can cause outbreaks in communities, with significant health, social and economic impact. Currently, serogroup B is the main cause of MD in Europe and North America and one of the most prevalent serogroups in Latin America. Mass vaccination strategies using polysaccharide vaccines have been deployed since the 1970s and the use of conjugate vaccines has controlled endemic and epidemic disease caused by serogroups A, C, W and Y and more recently serogroup B using geographically-specific outer membrane vesicle based vaccines. Two novel protein-based vaccines are a significant addition to our armamentarium against N. meningitidis as they provide broad coverage against highly diverse strains in serogroup B and other groups. Early safety, effectiveness and impact data of these vaccines are encouraging. These novel serogroup B vaccines should be actively considered for individuals at increased risk of disease and to control serogroup B outbreaks occurring in institutions or specific regions, as they are likely to save lives and prevent severe sequelae. Incorporation into national programs will require thorough country-specific analysis.
Bibliographical noteFunding Information:
RV: has received grants to support research projects from GSK. M.A.P.S. has received grants to support research projects and consultancy fee from GSK, Pfizer and Sanofi Pasteur. A.F. is an investigator in vaccine research projects funded by GSK, Pfizer and Sanofi Pasteur (funding paid to his employers). MO: has received grants to support research projects from GSK. JPT and MTV do not report any conflicts of interest.
© 2018 Taylor & Francis.
- Neisseria meningitidis
- meningococcal serogroup B
- meningococcal vaccines